Company: BNBX
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001410578-25-001814
Chunk: 5

Company: BNB PLUS CORP.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 2M
Chunk 5
---
ited condensed consolidated financial statements and notes thereto included in this Quarterly Report, those set forth from time to time in our other filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2024, and the following factors and risks:

●our expectations of future revenues, expenditures, capital or other funding requirements;

●the adequacy of our cash and working capital to fund present and planned operations and growth;

●the substantial doubt relating to our ability to continue as a going concern;

●our need for additional financing which may in turn require the issuance of additional shares of common stock, preferred stock or other debt or equity securities (including convertible securities) which would dilute the ownership held by stockholders;

●our identification of a material weakness in our internal control over financial reporting;

●our business strategy, including our concentration on Therapeutic DNA Production Services, which is unproven and for which demand may not materialize;

●the timing of our expansion plans, including the development of new production facilities for our nucleic-acid production solutions;

●demand for Therapeutic DNA Production Services;

●our expectations concerning existing or potential development and license agreements for third-party collaborations or joint ventures;